-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Insulet, Lowers Price Target to $326

Benzinga·02/19/2026 17:41:45
Listen to the news
Goldman Sachs analyst David Roman maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $363 to $326.